Browse > Article

Antitumor Activity of the Novel Human Cytokine AIMP1 in an in vivo Tumor Model  

Lee, Yeon-Sook (Division of Life Sciences, and Graduate School of Biotechnology, Korea University)
Han, Jung Min (Imagene Co. Ltd. Biotechnology Incubation Center, Seoul National University)
Kang, Taehee (Imagene Co. Ltd. Biotechnology Incubation Center, Seoul National University)
Park, Young In (Division of Life Sciences, and Graduate School of Biotechnology, Korea University)
Kim, Hwan Mook (Korea Research Institute of Bioscience and Biotechnology (KRIBB))
Kim, Sunghoon (National Creative Research Initiatives Center for ARS Network, College of Pharmacy Seoul National University)
Publication Information
Molecules and Cells / v.21, no.2, 2006 , pp. 213-217 More about this Journal
Abstract
Although AIMP1 (previously known as p43) is one of three auxiliary proteins bound to a macromolecular aminoacyl tRNA complex, it is also secreted as a cytokine controlling both angiogenesis and immune responses. Here we show that systemically administered purified recombinant human AIMP1 had anti-tumor activity in mouse xenograft models. In Meth A-bearing Balb/c mice, tumor volume increased about 28 fold in the vehicle treatment group, while an increase of about 16.7 fold was observed in the AIMP1-treated group. We also evaluated the anti-tumor activity of AIMP1 in combination with a sub-clinical dose of the cytotoxic anti-tumor drug, paclitaxel. The growth of NUGC-3 human stomach cancer cells was suppressed by 84% and 94% by the combinations of 5 mg/kg paclitaxel + 25 mg/kg AIMP1 (p = 0.03), and 5 mg/kg paclitaxel + 50 mg/kg AIMP1 (p = 0.02), respectively, while 5 mg/kg paclitaxel alone suppressed growth by only 54% (p = 0.02). A similar cooperative effect of AIMP1 and paclitaxel was observed in a lung cancer xenograft model. These results suggest that AIMP1 may be useful as a novel anti-tumor agent.
Keywords
AIMP1; Angiogenesis; Anticancer; EMAP II; p43; Tumor;
Citations & Related Records

Times Cited By Web Of Science : 6  (Related Records In Web of Science)
연도 인용수 순위
  • Reference
1 Chang, S. Y., Park, S. G., Kim, S., and Kang, C. Y. (2002) Interaction of the C-terminal domain of p43 and the alpha subunit of ATP synthase. Its functional implication in endothelial cell proliferation. J. Biol. Chem. 277, 8388–8394   DOI   ScienceOn
2 Gervaz, P. and Fontolliet, C. (1998) Therapeutic potential of the anti-angiogenesis drug TNP-470. Int. J. Exp. Pathol. 79, 359-362   DOI   ScienceOn
3 Kao, J., Houck, K., Fan, Y., Haehnel, I., Libutti, S. K., et al. (1994) Characterization of a novel tumor-derived cytokine. Endothelial-monocyte activating polypeptide II. J. Biol. Chem. 269, 25106-25119
4 Kato, T., Sato, K., Kakinuma, H., and Matsuda, Y. (1994) Enhanced suppression of tumor growth by combination of angiogenesis inhibitor O-(chloroacetyl-carbamoyl) fumagillol (TNP-470) and cytotoxic agents in mice. Cancer Res. 54, 5143-5147
5 Ko, Y. G., Park, H., Kim, T., Lee, J. W., Park, S. G., et al. (2001) A cofactor of tRNA synthetase, p43, is secreted to upregulate proinflammatory genes. J. Biol. Chem. 276, 23028-23033   DOI   ScienceOn
6 Folkman, J. (2003) Fundamental concepts of the angiogenic process. Curr. Mol. Med. 3, 643-651   DOI   ScienceOn
7 Park, S. G., Shin, H., Shin, Y. K., Lee, Y., Choi, E. C., et al. (2005) The novel cytokine p43 stimulates dermal fibroblast proliferation and wound repair. Am. J. Pathol. 166, 387-398   DOI   ScienceOn
8 Perrotte, P., Matsumoto, T., Inoue, K., Kuniyasu, H., Eve, B. Y., et al. (1999) Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin. Cancer Res. 5, 257–265
9 Schwarz, M. A., Kandel, J., Brett, J., Li, J., Hayward, J., et al. (1999) Endothelial-monocyte activating polypeptide II, a novel antitumor cytokine that suppresses primary and metastatic tumor growth and induces apoptosis in growing endothelial cells. J. Exp. Med. 190, 341-354   DOI   ScienceOn
10 Hayes, A. J., Li, L. Y., and Lippman, M. E. (1999) Science, medicine, and the future. Antivascular therapy: a new approach to cancer treatment. BMJ 318, 853-856   DOI
11 Moser, T. L., Kenan, D. J., Ashley, T. A., Roy, J. A., Goodman, M. D., et al. (2001) Endothelial cell surface F1-F0 ATP synthase is active in ATP synthesis and is inhibited by angiostatin. Proc. Natl. Acad. Sci. USA 98, 6656-6661
12 Quevillon, S., Agou, F., Robinson, J. C., and Mirande M. (1997) The p43 component of the mammalian multi-synthetase complex is likely to be the precursor of the endothelial monocyte-activating polypeptide II cytokine. J. Biol. Chem. 272, 32573–32579   DOI   ScienceOn
13 Inoue, K., Slaton, J. W., Davis, D. W., Hicklin, D. J., McConkey, D. J., et al. (2000) Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel. Clin. Cancer Res. 6, 2635-2643
14 Park, S. G., Kang, Y. S., Ahn, Y. H., Lee, S. H., Kim, K. R., et al. (2002) Dose-dependent biphasic activity of tRNA synthetaseassociating factor, p43, in angiogenesis. J. Biol. Chem. 277, 45243-45248   DOI   ScienceOn
15 Folkman, J. (2002) Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 29 (6 Suppl. 16), 15-18   DOI
16 Moser, T. L., Stack, M. S., Asplin, I., Enghild, J. J., Hojrup, P., et al. (1999) Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc. Natl. Acad. Sci. USA 96, 2811–2816
17 O'Reilly, M. S. (2002) The combination of antiangiogenic therapy with other modalities. Cancer J. 8 (Suppl. 1), S89-99
18 Ye, D., Mendelsohn, J., and Fan, Z. (1999) Augmentation of a humanized anti-HER2 Mab 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor Mab C225. Oncogene 18, 731-738   DOI   ScienceOn
19 Slaton, J. W., Perrotte, P., Inoue, K., Dinney, C. P., and Fidler, I. J. (1999) Interferon-a-mediated down-regulation of angiogenesis- related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin. Cancer Res. 5, 2726–2734